Material Agreements (Details) - USD ($) $ in Thousands								1 Months Ended	2 Months Ended	12 Months Ended		17 Months Ended	26 Months Ended	50 Months Ended
	Mar. 27, 2023	Mar. 02, 2023	Oct. 26, 2022	Sep. 26, 2022	Nov. 03, 2020	Oct. 23, 2020	May 21, 2020	Jun. 30, 2024	Dec. 31, 2020	Dec. 31, 2024	Dec. 31, 2023	Feb. 20, 2019	Dec. 31, 2022	Dec. 31, 2024	Sep. 30, 2022	May 17, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty obligations, net										$ 21,053	$ 33,896			$ 21,053
Revenues										57,561	50,583
Interest income and other income, net										$ 3,437	16,321
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]										Interest income and other income, net
Chief Executive Officer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs, monthly payment, duration																18 months
Assertio Holdings, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators			$ 9,000
Contingent consideration, milestone payments			$ 6,000
Manufacture and supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 39,976	43,805
License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 15,345	5,376
Commercial Exploitation Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement term										7 years
Automatic renewal period of agreement		1 year								1 year
Revenues											5,482
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative arrangement, excluding from revenue from contract with customer											11,482
Interest income and other income, net											6,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Manufacture and supply revenue | Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income, revenue recognized											$ 1,682
Supplemental Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues												$ 40,750
License Agreement with Sunovion Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues						$ 22,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues						17,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues							$ 4
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues						$ 5,000
Marathon Pangolin Royalty LLC | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net					$ 125,000
Marathon Pangolin Royalty LLC | Monetization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net					40,000				$ 10,000				$ 50,000	$ 50,000
Proceeds from debt, contingent on additional milestones					$ 75,000
Haisco Pharmaceutical Group Co., Ltd, Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, receivable, after allowance for credit loss															$ 7,000
Contract with customer, liability, revenue recognized								$ 7,000
Sales commissions and fees								$ 134
Atnahs Pharma UK Limited | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net				$ 3,500
Mitsubishi Tanabe Pharma America, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability, revenue recognized										$ 3,317
Sales commissions and fees										$ 57
Atnahs Pharma UK Limited, Amended Agreement | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net	$ 2